Cost-effectiveness of Screening Program for Chronic Q Fever, the Netherlands
| Autor: | Peter M. Schneeberger, Marit M A de Lange, Wim van der Hoek, Cornelia C. H. Wielders, Chantal P. Bleeker-Rovers, Jan Jelrik Oosterheert, Frederika Dijkstra, Pieter T de Boer, Sonja E van Roeden |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
economic evaluation Epidemiology Cost effectiveness Cost-Benefit Analysis lcsh:Medicine 0302 clinical medicine Chronic Q fever Prevalence Mass Screening Targeted screening 030212 general & internal medicine bacteria Netherlands Aged 80 and over biology Incidence (epidemiology) Age Factors Middle Aged Infectious Diseases Coxiella burnetii Female Cost-effectiveness of Screening Program for Chronic Q Fever the Netherlands Adult Microbiology (medical) 030231 tropical medicine Q fever Decision Support Techniques lcsh:Infectious and parasitic diseases Young Adult 03 medical and health sciences All institutes and research themes of the Radboud University Medical Center Environmental health medicine Humans lcsh:RC109-216 cost-effectiveness Mass screening Aged business.industry Research screening the Netherlands lcsh:R medicine.disease biology.organism_classification zoonoses lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] Economic evaluation business |
| Zdroj: | Emerging Infectious Diseases, Vol 26, Iss 2, Pp 238-246 (2020) Emerging Infectious Diseases, 26, 238-246 Emerging Infectious Diseases Emerging Infectious Diseases, 26, 2, pp. 238-246 |
| ISSN: | 1080-6040 |
| Popis: | In the aftermath of a large Q fever (QF) epidemic in the Netherlands during 2007-2010, new chronic QF (CQF) patients continue to be detected. We developed a health-economic decision model to evaluate the cost-effectiveness of a 1-time screening program for CQF 7 years after the epidemic. The model was parameterized with spatial data on QF notifications for the Netherlands, prevalence data from targeted screening studies, and clinical data from the national QF database. The cost-effectiveness of screening varied substantially among subpopulations and geographic areas. Screening that focused on cardiovascular risk patients in areas with high QF incidence during the epidemic ranged from cost-saving to €31,373 per quality-adjusted life year gained, depending on the method to estimate the prevalence of CQF. The cost per quality-adjusted life year of mass screening of all older adults was €70,000 in the most optimistic scenario. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|